Biogen Idec prepares for multiple launches in coming years

US biotech firm Biogen Idec (Nasdaq: BIIB) outlined its plans for driving the continued strong commercial performance of its existing multiple sclerosis (MS) treatments, preparing for the potential launches of multiple new high-impact therapies, advancing its late-stage pipeline, and leveraging its R&D capabilities to grow its early-stage pipeline at the JP Morgan Healthcare Conference in San Francisco.

“Biogen Idec had a remarkable year in 2011, which laid important groundwork for our future,” said chief executive George Scangos, speaking this week at the annual “beauty parade” for pharma and biotech companies. “We are poised for exceptional growth in the coming years, and we are focused on execution in 2012 to make sure we deliver on that promise. We are committed to growing our current portfolio of leading MS treatments, while we also invest in innovative science and pipeline programs with the greatest potential to improve the lives of patients with neurodegenerative diseases, hemophilia and autoimmune diseases.”

Focused on execution of four priorities